Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 25;10(2):e003776. doi: 10.1136/jitc-2021-003776

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See https://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Effect of combination treatment (ieramilimab +spartalizumab) on immune-related markers. (A) IHC and RNA sequencing data at baseline (n=75), (B) IHC and RNA sequencing fold change data (n=28), (C) IFN-γ expression by BOR at baseline (n=91).: BOR, best overall response; CR, complete response; CRC, colorectal cancer; HNSC, head-neck squamous cell carcinoma; IFN, interferon-γ; IHC, immunohistochemistry; NCRNPD, non-complete response/non-progressive disease (the presence of any non-target lesions or abnormal nodal lesions); PD, progressive disease; PR, partial response; SD, stable disease; UNK, unknown.